Alexandre Hohl

Alexandre Hohl

Auto-generated profile, based on publicly available information

Alexandre Hohl

Universidade Federal de Santa Catarina (UFSC)

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
AHAlexandre Hohl
Alexandre Hohl
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
MOMônica de Oliveira
Mônica de Oliveira
Hirsutism is defined as excessive terminal hair growth in androgen-dependent areas of the body in women, which grows in a typical male distribution pattern. Hirsutism is a common clinical problem in women, and the treatment depends on the cause. The condition is often associated with a loss of self-esteem. Hirsutism reflects the interaction between circulating androgen concentrations, local androgen concentrations, and the sensitivity of the hair follicle to androgens. Polycystic ovary syndrome and idiopathic hirsutism are the most common causes of the condition. A woman’s history and, physical examination are particularly important in evaluating excess hair growth. The vast majority of women with hirsutism have the idiopathic variety, and the diagnosis is made by exclusion. Serum testosterone level > 200 ng/dL is highly suggestive of adrenal or ovarian tumor. Treatment of hirsutism should be based on the degree of excess hair growth presented by the patient and in the pathophysiology of the disorder. Treatment includes lifestyle therapies, androgen suppression, peripheral androgen blockage, and cosmetic treatments. The current review discusses definition, pathogenesis, physiopathology, differential diagnosis, diagnostic strategies, and treatment.

14 July 2017 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MBMarcello Casaccia Bertoluci
Marcello Casaccia Bertoluci
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
AFAndré Faludi
André Faludi
Maria Cristina IzarMaria Cristina Izar
Maria Cristina Izar
BSBeatriz Schaan
Beatriz Schaan
RSRaul D Santos
Raul D Santos
Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratification in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-based approach on treatment for patients with diabetes. The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations covering: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the use of antiplatelet therapy. Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protection from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized according to cardiovascular risk while intensification of treatment should focus on those at higher risk.

1 November 2009 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
AHAlexandre Hohl
Alexandre Hohl
TMTânia Longo Mazzuco
Tânia Longo Mazzuco
MCMarisa Helena César Coral
Marisa Helena César Coral
MSMarcelo Schwarzbold
Marcelo Schwarzbold
RWRoger Walz
Roger Walz
Traumatic brain injury (TBI) is the most common cause of death and disability in young adults. Post-TBI neuroendocrine disorders have been increasingly acknowledged in recent years due to their potential contribution to morbidity and, probably, to mortality after trauma. Marked alterations of the hypothalamic-pituitary axis during the post-TBI acute and chronic phases have been reported. Prospective and longitudinal studies have shown that some abnormalities are transitory. On the other hand, there is a high frequency (15% to 68%) of pituitary hormone deficiency among TBI survivors in a long term setting. Post-TBI hypogonadism is a common finding after cranial trauma, and it is predicted to develop in 16% of the survivors in the long term. Post-TBI hypogonadism has been associated with adverse results in the acute and chronic phases after injury. These data reinforce the need for identification of hormonal deficiencies and their proper treatment, in order to optimize patient recovery, improve their life quality, and avoid the negative consequences of non-treated hypogonadism in the long term.

12 July 2019 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
RWRita V. Weiss
Rita V. Weiss
AHAlexandre Hohl
Alexandre Hohl
AAAmanda Athayde
Amanda Athayde
DPDolores Pardini
Dolores Pardini
LGLarissa Gomes
Larissa Gomes
PSPoli Spritzer
Poli Spritzer
Key words: Testosterone therapy; female sexual disorder; position

7 May 2019 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
FRFernanda Augustini Rigon
Fernanda Augustini Rigon
MRMarcelo Fernando Ronsoni
Marcelo Fernando Ronsoni
AHAlexandre Hohl
Alexandre Hohl
SSSimone van de Sande-Lee
Simone van de Sande-Lee

24 May 2020 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MBMarcello Casaccia Bertoluci
Marcello Casaccia Bertoluci
JSJoão Eduardo Nunes Salles
João Eduardo Nunes Salles
JSJose Silva-Nunes
Jose Silva-Nunes
HPHermelinda Cordeiro Pedrosa
Hermelinda Cordeiro Pedrosa
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
CLCristiane Bauermann Leitão
Cristiane Bauermann Leitão
Background: In current management of type 2 diabetes (T2DM), cardiovascular and renal prevention have become important targets to be achieved. In this context, a joint panel of four endocrinology societies from Brazil and Portugal was established to develop an evidence-based guideline for treatment of hyperglycemia in T2DM.Methods: MEDLINE (via PubMed) was searched for randomized clinical trials, meta-analyses, and observational studies related to diabetes treatment. When there was insufficient high-quality evidence, expert opinion was sought. Updated positions on treatment of T2DM patients with heart failure (HF), atherosclerotic CV disease (ASCVD), chronic kidney disease (CKD), and patients with no vascular complications were developed. The degree of recommendation and the level of evidence were determined using predefined criteria.Results and conclusions: In non-pregnant adults, the recommended HbA1ctarget is below 7%. Higher levels are recommended in frail older adults and patients at higher risk of hypoglycemia. Lifestyle modification is recommended at all phases of treatment. Metformin is the first choice when HbA1cis 6.5–7.5%. When HbA1cis 7.5–9.0%, dual therapy with metformin plus an SGLT2i and/or GLP-1RA (first-line antidiabetic agents, AD1) is recommended due to cardiovascular and renal benefits. If an AD1 is unaffordable, other antidiabetic drugs (AD) may be used. Triple or quadruple therapy should be considered when HbA1cremains above target. In patients with clinical or subclinical atherosclerosis, the combination of one AD1 plus metformin is the recommended first-line therapy to reduce cardiovascular events and improve blood glucose control. In stable heart failure with low ejection fraction (< 40%) and glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2, metformin plus an SGLT-2i is recommended to reduce cardiovascular mortality and heart failure hospitalizations and improve blood glucose control. In patients with diabetes-associated chronic kidney disease (CKD) (eGFR 30–60 mL/min/1.73 m2or eGFR 30–90 mL/min/1.73 m2with albuminuria > 30 mg/g), the combination of metformin and an SGLT2i is recommended to attenuate loss of renal function, reduce albuminuria and improve blood glucose control. In patients with severe renal failure, insulin-based therapy is recommended to improve blood glucose control. Alternatively, GLP-1RA, DPP4i, gliclazide MR and pioglitazone may be considered to reduce albuminuria. In conclusion, the current evidence supports individualizing anti-hyperglycemic treatment for T2DM.